Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Sandoz Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (682)
Cancellation by sponsor (321)
Prescription medicine registration (54)
Section 14, TGO91 consent (17)
Cancellation or suspension (8)
Australian Public Assessment Report (AusPAR) (4)
Prescription medicine decision summary (1)

Date

2024 (82)
2023 (78)
2022 (67)
2021 (121)
2020 (153)
2019 (53)
2018 (60)
2017 (50)
2016 (4)
2015 (39)
2014 (20)
2013 (24)
2012 (13)
2011 (51)
2010 (47)
2009 (37)
2008 (27)
2007 (21)
2006 (21)
2005 (54)
2004 (12)
2003 (10)
2002 (10)
2001 (6)
2000 (5)
1999 (5)
1998 (9)
1997 (4)
1991 (3)

Results for "[search-keyword]"

Search

Sponsor content

1087 result(s) found, displaying 691 to 700

OXALIPLATIN EBEWE oxaliplatin 100mg powder for injection vial Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
APO-AMOXYCILLIN and CLAVULANIC ACID 125/31.25 powder for suspension bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
APO-AMOXYCILLIN and CLAVULANIC ACID 400/57 powder for suspension bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
CALCITRIOL SANDOZ calcitriol 0.25 microgram capsule bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 200mg/20mL solution for injection ampoule Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 40mg/20mL solution for injection ampoule Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 100mg/10mL solution for injection ampoule Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 150mg/20mL solution for injection ampoule Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
ROPIVACAINE SANDOZ ropivacaine hydrochloride (as monohydrate) 20mg/10mL solution for injection ampoule Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd
OXALIPLATIN EBEWE oxaliplatin 50 mg/10 mL concentrated injection vial Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Sandoz Pty Ltd

Pages

First page
Previous page
…
Page 66
Page 67
Page 68
Page 69
Current page 70
Page 71
Page 72
Page 73
Page 74
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.